TRT denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for trt are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Testosterone Replacement Therapy as Non-Formulary — and How to Appeal

Testosterone replacement therapy (TRT) is available in multiple FDA-approved formulations — injectables, topical gels and creams, patches, pellets, and buccal products. UnitedHealthcare's formulary (drug list) covers certain TRT formulations at preferred tiers and excludes or restricts others. A non-formulary denial means the specific product your prescriber chose is not on UHC's covered drug list for your plan, even though other TRT products may be covered.

### Why This Denial Is Appealable

Non-formulary denials are overturned through a formulary exception process when a covered formulary alternative is not clinically appropriate for you. If you have already tried the formulary alternative and it failed, was not tolerated, or is medically inappropriate for a specific reason (such as an administration route that is not feasible for your situation), that clinical basis supports a formulary exception. The appeal is not about whether TRT as a class is necessary — it is about why this specific formulation is necessary for you.

### Federal Appeal Framework

• Formulary exception request: Submit this to UHC before or alongside the formal internal appeal — it is the primary pathway for non-formulary drugs.
• Internal appeal: If the exception is denied, a formal internal appeal follows. UHC must decide standard appeals within 30 days and urgent/expedited appeals within 72 hours.
• External review (ACA §2719): After final internal denial, an independent IRO reviews the denial applying clinical evidence standards.
• ERISA §503: Full-and-fair review rights apply for employer-sponsored plans; you are entitled to the criteria and clinical rationale used.
• Timeline: File external review within approximately four months of the final internal denial. Expedited review is available when delay poses a health risk.

### Concrete Appeal Steps

1. Identify which TRT formulations are on UHC's current formulary — this is in your plan's drug list or available from UHC member services. 2. With your prescriber, document any clinical reason why the formulary alternative is not appropriate (prior failure, tolerability issue, administration barrier). 3. Submit a formulary exception request with a prescriber letter. 4. If denied, file a formal internal appeal adding the FDA prescribing label and clinical necessity documentation. 5. Escalate to external review if the internal appeal fails.

### Documentation to Gather

• Diagnosis confirmation: Lab and chart documentation of hypogonadism diagnosis.
• Prior formulary alternative trial: If you tried the covered formulary product: dates, doses, outcomes, and reason for switching.
• Clinical reason for specific formulation: Prescriber documentation of why this route of administration or specific product is required — for example, compliance considerations, skin condition precluding topical use, or documented tolerability problem with the alternative.
• Prescriber medical-necessity letter: Addressing both the underlying diagnosis and the clinical reason this non-formulary product is necessary over the formulary option.

### Criteria-Mapping Structure

Obtain UHC's formulary exception criteria and map each requirement to documentation:

| UHC Formulary Exception Requirement | Supporting Documentation | |---|---| | [Copy each requirement from UHC's exception policy] | [Chart note, date, prescriber letter reference] |

Review the FDA-approved prescribing labels for both the prescribed product and the formulary alternative at DailyMed — differences in labeled indications, contraindications, or administration requirements may support the exception.